Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) announces a share repurchase program. Under the program, the company will repurchase not more than CNY 40 million worth of its shares. The shares will be repurchased at a price not more than CNY 8 per share. The shares repurchased will be used for equity incentive plan and/or employee stock ownership plan. The program will be funded from company's own funds. The program will be valid for 12 months.

On June 2, 2023, the company amended its share repurchase program. The shares will be repurchased at a price not exceeding CNY 7.99 per share.